News

#Dow Jones Newswires: Enhertu significantly delayed breast cancer progression in trial, AstraZeneca says

Table of Contents

“Dow Jones Newswires: Enhertu significantly delayed breast cancer progression in trial, AstraZeneca says”

AstraZeneca PLC said Monday that its Enhertu drug significantly delayed metastatic breast cancer progression in a Phase 3 trial, reinforcing the results of a prior trial.

The Anglo-Swedish pharma giant
AZN,
+2.61%
said results from the Destiny-Breast02 Phase 3 trial of Enhertu–trastuzumab deruxtecan–showed the trial met the primary endpoint, demonstrating a significant and clinically meaningful improvement in progression-free survival in patients.

Enhertu is being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo Ltd.

Write to Kyle Morris at [email protected]

Kyle Morris

If you liked the article, do not forget to share it with your friends. Follow us on Google News too, click on the star and choose us from your favorites.